CTOs on the Move

NeuBase Therapeutics

www.neubasetherapeutics.com

 
NeuBase is developing ultra precision genetic medicines targeting rare, monogenic diseases, therapeutic candidates for the treatment of myotonic dystrophy type 1 (DM1), Huntington`s disease (HD), and cancer-driving point mutations in KRAS G12V and G12D, which are involved in many tumor types and have historically been “undruggable.” for which there are no approved therapies, as well as more common genetic disorders, including cancers that are resistant to current therapeutic approaches. NeuBase`s pipeline includes
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details
Anthony Rossomando
Chief Technology Officer Profile

Similar Companies

Zura Bio Limited

Zura Bio is a clinical stage biotechnology company focused on developing ZB 168, an anti IL7Rα inhibitor, for the treatment of alopecia areata and other inflammatory diseases.

International Stem Cell Corporation

International Stem Cell Corporation is a Carlsbad, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

TMS International

TMSi is specialized in developing of high-quality measurement systems for electrophysiological parameters such as EEG and High Density EMG. Our systems are highly versatile and have the best data quality possible.

Premier Research

Premier Research is a Philadelphia, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

DYSIS Medical

DYSIS is a computer-aided colposcope with innovative cervical mapping to help healthcare professionals clearly detect cervical lesions